List of Gene Therapy Companies in Sweden - 13

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers.

Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymes™ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATOR™, FabALACTICA™, GingisKHAN™, FabULOUS™ & FabRICATOR Z™ General proteolysis - GingisREX™ De-glycosylation and conjugation of IgGs - GlycINATOR™, IgGZERO™ and GlyCLICK™ O-glycan analysis - OglyZOR™, OpeRATOR™, GlycOCATCH™ and SialEXO™

Gyros Protein Technologies provides enabling peptide synthesis and bioanalytical solutions helping scientists increase biomolecule performance and productivity in pre-clinical/clinical development and bioprocess applications. The automat

Hansa Biopharma, is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative and life altering treatments for patients with rare immunological conditions. Hansa scientists are working on developing immunomodulatory treatments for organ transplants, rare IgG-mediated autoimmune conditions, and gene therapy, as well as exploring the potential application of the technology platform in oncology.

The company is developing immunotherapies that use microorganisms to deliver stable therapeutic proteins

LOKON PHARMA is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer-based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

Developing state-of-the-art AAV vectors for gene therapy

Recipharm is a leading global CDMO dedicated to meeting your evolving needs through operational excellence, scientific know-how, and customer connectivity. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering. Our worldwide reach paired with in-depth, localised market knowledge allows us to anticipate our customers’ needs and strengthen the support we provide to forge a healthier, more expansive and more fruitful future together. With a workforce of 5 200 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. Since our inception in 1995, we have supported our customers throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again to ensure their products are delivered with certainty.

SmartCella, founded in 2014, is an innovative biotechnology and medtech company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.

For customers working in the life sciences and pharma industry, Svar offers a unique combination of scientific expertise, high-quality assay products, strong services, and proprietary technology platforms that provide a flexible, effective, and seamless experience for customers through different development needs in a way that no other single business can. At Svar, we are dedicated to our customers' development journey. We harness a deep understanding and long-standing experience in immunological areas such as complement system activation and immunogenicity. We utilize this in our expert cell engineering, assay development, and contract research services capabilities. Our specialist knowledge allows us to help you tackle complex problems, safely and efficiently moving your candidates through the drug development phases and to the patient—also when standard solutions fall short.

Cell metabolism and monitoring made easy - label-free and continuous measurements of biological activity. Multi-channel assay that measures the specific metabolic phenotype for cells and pathogens in real-time with exceptional precision. Return to phenotype - The calScreener™ cell-based assay provides a phenotype response measurement with unprecedented sensitivity and versatility. We enable: Smarter drug development - Bridge the gap between in-vitro and in-vivo testing Rapid and accurate diagnostic - Customize treatments for infections due to multi-resistant bacteria Want to see what others cannot? All living cells produce heat during metabolism. We measure this heat at unsurpassed precision. No heat equals no metabolism. The only absolute measurement of death. We make it possible to see what was previously impossible. Applications are limited only by the imagination of the scientist. Bacteria. Cells. Organoids. Worms. Ants. Feces. If it fits in the tube we can measure it. Symcel is a biotechnology company located in Stockholm and was founded by Dr. Dan Hallen and Prof. Ingemar Wadsö in 2004, leading authorities in the field of biocalorimetry.